Hepatitis C: epidemiology and review of complementary/alternative medicine treatments.
Hepatitis C is emerging as a serious worldwide problem. In the United States the current mortality figures may triple in the next ten years, rivaling HIV. The disease has a latency of 10-30 years and symptoms or signs may not appear until cirrhosis is evident. Adequate diagnosis, including liver biopsy, is essential in assessing the current stage of the viral infection and the need for treatment. Hepatitis C may manifest as hepatic fibrosis, cirrhosis, hepatocellular carcinoma, lichen planus, glomerulonephritis, mixed cryoglobulinemia, or porphyria. The hepatic damage is due both to the cytopathic effect of the virus and the inflammatory changes secondary to immune activation. The use of the botanical components glycyrrhizin, catechin, silymarin and phytosterols, and the antioxidants N-acetylcysteine and vitamin E are reviewed for their efficacy in treating chronic hepatitis and affecting liver damage.
Patrick
L
L
D000975:Antioxidants / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D002392:Catechin / Q000627:therapeutic use; D000529:Complementary Therapies; D018450:Disease Progression; D019695:Glycyrrhizic Acid / Q000627:therapeutic use; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D006801:Humans; D010840:Phytosterols / Q000627:therapeutic use; D010936:Plant Extracts / Q000627:therapeutic use*; D012254:Ribavirin / Q000627:therapeutic use; D012838:Silymarin / Q000627:therapeutic use
D000975:Antioxidants; D000998:Antiviral Agents; D010840:Phytosterols; D010936:Plant Extracts; D012838:Silymarin; D012254:Ribavirin; D019695:Glycyrrhizic Acid; D002392:Catechin